Smart device sold separately.
See why Dexcom is the right choice for optimizing glucose control.
Dexcom is dedicated to developing innovative glucose sensing technology and products to help patients and healthcare providers better manage diabetes.
As the provider of the number one patient-preferred CGM system,1 Dexcom invites you to take a look at the Dexcom G6, a revolution in diabetes management.
Whether sleeping, exercising, working or at school, there are times when patients can’t check their glucose levels. The customizable low and high glucose warnings, predictive Urgent Low Soon alert, and data sharing capability provided by the Dexcom G6 allow patients or their caregivers to take action and protect against hypo and hyperglycemia.II
Medical Benefit Coverage
Coverage of CGM for type 1 diabetes is offered for 98% of commercially insured patients, and many plans also provide coverage for people with insulin-using type 2 diabetes.¶ Additionally, Dexcom G5 CGM is the first therapeutic CGM system covered as a Medicare benefit.
Pharmacy Benefit Coverage
Dexcom G6 CGM is covered as a pharmacy benefit by the top pharmacy benefit managers (PBMs), and we are continuing to expand access through partnerships with regional and national health plans. For patients with CGM covered as a pharmacy benefit, their Dexcom G6 CGM prescription may be processed at local retail pharmacies.
The factory-calibrated Dexcom G6 gives your patients the freedom to manage diabetes without the hassle of fingersticks for calibrations or treatment decisions.*
*If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
*% of CGM readings within ±15 mg/dL of YSI lab reference values ≤ 100mg/dL or ±15% of YSI values > 100mg/dL.
†Analogous to %15/15 (see previous footnote).
‡MARD is a statistical measure of accuracy; the lower the number, the better.
§Unless noted otherwise, adult and pediatric data are combined.
IITreatment decisions should not be made based on Dexcom Follow.
¶Dexcom internal data on file
1dQ&A Diabetes Connections Panel Report, Q4 2017
2Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Well-Controlled Adults With Type 1 Diabetes. Diabetes Care. 2017.
3Šoupal J, Petruželková L, Fleka M et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technology & Therapeutics. 2016;18(9):532-538.
4Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomised Clinical Trial. JAMA. 2017;317(4):371-378.
5Lind M, Polonsky W, Hirsch IB, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomised Clinical Trial. JAMA. 2017;317(4):379-387.
6Reddy M, Jugnee N, El Laboudi A, Spanudakis E, Anantharaja S, Oliver N. A randomised controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia. Diabet Med. 2017.
7Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018.
8Shah VN, Laffel LM, Wadwa RP, Garg SK. Performance of a Factory-Calibrated Real-Time Continuous Glucose Monitoring System Utilizing an Automated Sensor Applicator. Diabetes Technol Ther. 2018.
9Wadwa RP, Laffel LM, Shah VN, Garg SK. Accuracy of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System During 10 Days of Use in Youth and Adults with Diabetes. Diabetes Technol Ther. 2018.